Can you take Curcumin (turmeric) and Sulforaphane together?

Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

Rankings / Comparisons

Curcumin (turmeric) vs Sulforaphane

Two of the most-studied food-derived anti-inflammatory / Nrf2-activating compounds.

Reviewed by Read Off Label · How we grade

Bottom line

On the composite score, Sulforaphane (B+, 7.1/10) edges out Curcumin (turmeric) (C+, 5.5/10) — but the right pick depends on the specific outcome you're optimising for.

Curcumin (turmeric)

C+ 5.5/10

Evidence: Moderate (osteoarthritis pain — multiple MAs show non-inferiority vs NSAIDs and significant WOMAC/VAS reduction; counter-intuitively 2025 network MA found bioavailability-enhanced forms did NOT outperform conventional in OA — WMD -2.47 vs -3.17); Moderate (NAFLD/MASLD — phytosomal curcumin specifically improved ALT/AST and ultrasound findings in RCTs; 2025 MA pooled ALT -5.61 U/L AST -3.90 U/L); Moderate (depression adjunct; metabolic syndrome markers); Weak (cardiovascular outcomes) (6/10)
Benefit: Med (5/10)
Risk: Med (the formulation paradox — hepatotoxicity case reports are concentrated in HIGH-bioavailability formulations: Italian Phytovigilance / Tuscany cluster, DILIN 10-case US series, Icelandic case reports — most linked to Meriva/phytosome or piperine-boosted products at standard supplement doses; rare idiosyncratic non-infectious cholestatic hepatitis; iron chelation potential; theoretical anticoagulant interactions) (5/10 safety)
Legality: OTC (EFSA ADI 180 mg curcumin/day for 60 kg adult ≈ 3 mg/kg/day; Italian Ministry of Health required new hepatotoxicity warning labels 2024-2025)
Dose: 500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine 5-20 mg co-admin (~20x); phytosome/Meriva (~20-29x AUC); BCM-95 (~7x); Theracurmin (~27x AUC and ~5.6x Cmax vs Meriva); NovaSol micelle (very high Cmax with rapid decline)
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades Curcumin (turmeric) as C+ (5.5/10) based on moderate evidence, med benefit magnitude, and a med-risk safety profile.

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted.

Typical use: 500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine 5-20 mg co-admin… — OTC.

What it is

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted. **The formulation paradox is the central biohacker decision input**: bioavailability-enhanced forms (Meriva/phytosome; Theracurmin; BCM-95; NovaSol; piperine-boosted) deliver 5-30x higher plasma curcumin, but hepatotoxicity case reports are CONCENTRATED in exactly these formulations. EFSA, Italian Phytovigilance, DILIN, and Icelandic case clusters all point the same direction — bioavailability-enhanced products at standard supplement doses produce occasional idiosyncratic cholestatic hepatitis. EFSA's 180 mg/day ADI is below typical biohacker dosing. Italian Ministry of Health required new warning labels on Curcuma longa supplements 2024-2025. **OA paradox**: 2025 network MA on knee OA (17 studies) found conventional curcuminoid preparations had numerically LARGER WOMAC pain reduction (-3.17) than bioavailability-enhanced ones (-2.47) — complicates the "phytosomal is better" supplement-industry narrative. NAFLD/MASLD is the strongest specific indication for phytosomal curcumin per the 2025 ALT/AST pooled MA. **Practical read of 2024-2025 evidence**: (a) prefer conventional curcuminoids at moderate doses with food/fat; (b) stay below the EFSA ADI of ~3 mg/kg/day; (c) monitor LFTs if using bioavailability-enhanced forms long-term; (d) hold immediately if jaundice/dark urine/RUQ pain. Phytosomal/Meriva remains reasonable for NAFLD-targeted use under monitoring; for general anti-inflammatory or OA use, conventional is now better-justified.

Mechanism

Diferuloylmethane polyphenol from Curcuma longa; pleiotropic effects — NF-κB; COX-2; 5-LOX; JAK-STAT; Nrf2 inhibition/activation across dozens of pathways; native curcumin has <1% oral bioavailability and is rapidly conjugated/excreted; formulation strategies (phytosome, micelle, nanoemulsion, piperine co-administration) raise plasma exposure 5-30x

Full Curcumin (turmeric) review →

Sulforaphane

B+ 7.1/10

Evidence: Moderate (autism — 2025 meta-analysis n=333 across 6 RCTs significant SRS reduction at both 4-5 and 8-10 weeks; Singh 2014 the canonical anchor); Moderate (airborne carcinogen excretion — Kensler 2014 Qidong China demonstrated bladder excretion of acrolein/benzene/crotonaldehyde metabolites); Moderate (schizophrenia negative symptoms and cognition — 2025 RCT positive in chronic schizophrenia); Weak-Moderate (cancer — early-stage prostate and breast signal especially in GSTM1-positive individuals, limited in advanced disease); Moderate (metabolic markers and inflammation across multiple smaller trials) (6/10)
Benefit: Med (5/10)
Risk: Low (well-tolerated; rare GI symptoms; ~50% of completed sulforaphane trials remain unpublished — publication bias caveat from 2025 JNS comprehensive review) (9/10 safety)
Legality: OTC (broccoli sprout extract; preformed sulforaphane products include Avmacol, Prostaphane, BroccoMax)
Dose: 10-40 mg sulforaphane equivalent/day; broccoli sprouts ~30 g/day; or preformed (Avmacol/Prostaphane)
Class: Supplement
Last reviewed: Jun 8, 2026

Read Off Label grades Sulforaphane as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.

Solid Nrf2-pathway activation with the broadest evidence base of any phytochemical Nrf2 activator.

Typical use: 10-40 mg sulforaphane equivalent/day; broccoli sprouts ~30 g/day; or preformed (Avmacol/Prostaphane) — OTC.

What it is

Solid Nrf2-pathway activation with the broadest evidence base of any phytochemical Nrf2 activator. **Foundational trials**: Singh 2014 (PNAS) autism RCT and Kensler 2014 Qidong air-pollution carcinogen-detox trial remain pivotal anchors. **2024-2025 evidence update**: comprehensive 2025 JNS systematic review (PMID 40988712) catalogued 84 ClinicalTrials.gov-registered sulforaphane trials of which 39 published — flagged a meaningful ~50% publication gap that biohacker writeups systematically miss. 2025 autism meta-analysis (PMC12127520) — n=333 across 6 RCTs confirmed significant Social Responsiveness Scale reduction at both 4-5 and 8-10 weeks. 2025 schizophrenia RCT in chronic patients (J Psychiatr Res) showed significant improvement in negative symptoms and cognition. Cancer evidence remains GSTM1-genotype-stratified — early-stage prostate and breast benefit in GSTM1-positive patients, limited in advanced disease. **Formulation caveat (central practical input)**: native sulforaphane is highly unstable — buy preformed sulforaphane products (Avmacol, Prostaphane) OR pair glucoraphanin supplements with active myrosinase (typically broccoli sprout extract). Powdered broccoli/glucoraphanin without active myrosinase is largely useless because gastric pH inactivates the enzyme.

Mechanism

Isothiocyanate from broccoli sprouts hydrolyzed from glucoraphanin by myrosinase; activates Nrf2-ARE pathway — upregulates phase II detoxification and antioxidant enzymes (GST/NQO1/HO-1); reversible HDAC inhibitor; autophagy inducer; mitochondrial biogenesis support; native instability requires preformed sulforaphane or co-delivery with active myrosinase

Full Sulforaphane review →

Common questions

Which is better, Curcumin (turmeric) or Sulforaphane?: On the composite score, Sulforaphane (B+, 7.1/10) edges out Curcumin (turmeric) (C+, 5.5/10) — but the right pick depends on the specific outcome you're optimising for.
What's the difference between Curcumin (turmeric) and Sulforaphane?: Two of the most-studied food-derived anti-inflammatory / Nrf2-activating compounds.
Can you take Curcumin (turmeric) and Sulforaphane together?: Read Off Label doesn't make stack recommendations — see the disclaimer. Both compounds have individual mechanism, dose, and risk profiles documented on their respective pages; combining them is a clinical question that depends on the goal, indication, and other context.

This is an independent synthesis of published research by a non-clinician. Comparison-page verdicts use the composite Read Off Label score as a tiebreaker, but the right pick for any given person depends on indication, context, and clinician input. See the full disclaimer and methodology.